Tazemetostat
All the need-to-know items about the latest #oncopharm approved drug, tazemetostat, to start the Pod. We end (9:15) with a brief discussion of how gut bacteria may lead to gemcitabine resistance.
Jan 30, 2020•14 min
OncoPharm
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
Bendamustine
Foundations of OncoPharm: Bendamustine
Jan 23, 2020•17 min
Avapritinib
New Drug Update! We discuss the efficacy and safety data surrounding avapritinib's approval as well as its likely role in GIST management.
Jan 16, 2020•16 min
Safety Signals & 6 - MP Hepatotoxicity
How common are upon safety concerns from FDA on newly approved #oncopharm agents? Does the accelerated approval process lead to more safety updates? We discuss (https://doi.org/10.1634/theoncologist.2019-0653). We also look at a possible way to mitigate 6-MP hepatoxicity (5:45) using allopurinol (https://doi.org/10.1080/10428194.2019.1702183). Finally (10:55) we review the most recent FDA indications for olaparib and pembrolizumab.
Jan 09, 2020•16 min
Trastuzumab Deruxtecan
Kicking off the 2020 Pod season with the last FDA-approval of 2019 - trastuzumab deruxtecan.
Jan 02, 2020•13 min
Enfortumab-vedotin (& Asciminib)
Closing out the year discussing FDA's approval of enfortumab-vedotin for urothelial cancer and a new, but pharmacologically unique, TKI with activity in CML (12:45). Happy New Year!
Dec 26, 2019•16 min
Arsenic Sauce
The Foundations of #OncoPharm series combines with a thematic critique of an animated Holiday classic to examine the links between The Grinch and Arsenic Trioxide.
Dec 19, 2019•15 min
ASH '19 Updates
Reviewing pertinent abstracts from ASH's 2019 annual meeting. Abstracts discussed: LBA-1 (blinatumomab), 2640 (venetoclax-azoles interactions), 2639 (FLAG/CLAG vs. CPX-351 in sAML), LBA-6/862/860 (myeloma), and 3310 (PK-targeted dosing of melphalan for autoHSCT). Search here: https://ash.confex.com/ash/2019/webprogram/start.html
Dec 12, 2019•21 min
Dose Dense AC
The Landmarks in #OncoPharm series returns with dose-dense AC, published in JCO in 2003 by Citron et al. Link: https://www.ncbi.nlm.nih.gov/pubmed/12668651
Dec 05, 2019•17 min
Cornucopia Of OncoPharm Updates
The menu: sirolimus vs. prednisone for standard risk aGVHD, levofloxacin prophylaxis in myeloma patients (9:00), acalabrutinib's approval for CLL/SLL (12:00), OS analysis from osimertinib's FLAURA (14:30), optimal sequencing of abiraterone & enzalutamide (23:20), some novel non-malignant heme drugs (26:45), outro music (30:00), 2 new drugs for sickle cell (30:30), pecan pie.
Nov 27, 2019•36 min
Zanubrutinib
BTK-targeting therapy approved again! Zanubrutinib approved for Mantle Cell Lymphoma (2nd line) - how does it compare to ibrutinib and acalabrutinib?
Nov 21, 2019•20 min
Immunotherapy Interactions
Examining the effects of antibiotics, corticosteroids (6:45), and cannabis (12:05) on immunotherapy effectiveness.
Nov 14, 2019•16 min
Data Dive Into NK-1 Antagonists & Carboplatin
ASCO's updated 2017 antiemetic guidelines recommend NK-1 antagonists to prevent CINV with standard Q 3 week carboplatin (i.e. AUC 5-6), but how good are the data to support that? We dive into the supporting data.
Nov 07, 2019•17 min
Carboplatin
The basic must-know information for carboplatin, for students, residents, or anyone looking for a refresher.
Oct 31, 2019•21 min
ADAM VTE & Ibrutinib CV Toxicity
ADAM VTE (apixaban for cancer-associated VTE) results have been published - let's talk about it. Also, what are the implications of long term ibrutinib on CV health? A new Blood paper offers some possible answers.
Oct 24, 2019•18 min
To Rechallenge, Or Not To Rechallenge
Weighing the risks & benefits of immunotherapy rechallenge in patients with a prior immune-related adverse event (irAE). Reference: https://www.ncbi.nlm.nih.gov/pubmed/31461381
Oct 17, 2019•15 min
CASPIAN
Reviewing the recent Lancet publication of CASPIAN (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext) --> durvalumab + chemo in extensive stage small cell lung cancer.
Oct 10, 2019•11 min
ESMO 2019
Recapping updates from ESMO 2019. Topics include FLAURA (osimertinib), 5-year OS analyses of immunotherapy in metastatic NSCLC & melanoma, EGFR/BRAF/MEK inhibition in BRAF-V600E colorectal cancer, PARP inhibitors in ovarian cancer, and a possible cabazitaxel comeback.
Oct 03, 2019•22 min
Danorubicin 90 mg/m2 (AML induction)
The Landmarks in #Oncopharm series returns on the 10-year anniversary of this landmark paper (https://www.nejm.org/doi/10.1056/NEJMoa0904544) comparing daunorubicin 90 mg/m2 vs. 45 mg/m2 for AML induction.
Sep 24, 2019•14 min
New FDA approved indications for lenvatinib, pembro, and apalutamide
Discussion of FDA's approval of lenvatinib & pembrolizumab for endometrial cancer followed by a comparison of TITAN v. ENZAMET prompted by apalutamide's latest approval.
Sep 19, 2019•17 min
Curious Case Of Ibrutinib On Netflix
Recapping the NY Times (https://www.nytimes.com/interactive/2018/10/26/magazine/netflix-diagnosis-series-joe.html) & Netflix collaboration "Diagnosis" about a possible Ibrutinib ADR. We also the discuss the value of case reports for the #OncoPharm community.
Sep 12, 2019•16 min
OncoPharm M & M Extreme Toxicity & Pharmacogenetics
The 2nd installment of the OncoPharm Morbidity & Mortality series discussed a published case report (https://www.ncbi.nlm.nih.gov/pubmed/28782406). We discuss the approach to take when a patient experiences unexpectedly extreme toxicity and the role pharmacogenetics may play. Suggested resource: https://cpicpgx.org
Sep 05, 2019•13 min
Irinotecan
The Foundations of #OncoPharm series returns with all the must-know information for irinotecan.
Aug 29, 2019•17 min
Entrectinib & Fedratinib
Running through the drug information highlights of the latest approved #oncopharm agents: entrectinib and fedratinib.
Aug 22, 2019•19 min
E1912: Ibrutinib/rituximab vs. FCR in CLL
This week we look at the NEJM publication earlier this month (https://www.nejm.org/doi/full/10.1056/NEJMoa1817073) of E1912. Points of discussion include IGHV mutational status, PFS vs. OS as endpoints in CLL, the benefit of rituximab in addition to ibrutinib, and ibrutinib toxicity in younger vs. older CLL patients. (Also, apologies to my APPE student for dropping this Pod *after* your journal club on this paper.)
Aug 15, 2019•19 min
ASCO VTE Guidelines (& more!)
Updates on ASCO's updated VTE guidelines with a focus on prophylaxis for ambulatory cancer patients (1:15) and VTE treatment (12:50). Pembrolizumab's latest FDA-approval is discussed (16:00), as is pexidartinib's FDA-approval (18:00), and finally a comparison of BCOP pass rates by training status (22:34).
Aug 08, 2019•27 min
Darolutamide
Darolutamide has been FDA-approved. We discuss its differences and similarities to other 2nd-generation anti-androgens (enzalutamide & apalutamide) - especially potential drug interactions!
Jul 31, 2019•17 min
AC - - > T (q week)
Our Landmarks in #OncoPharm series returns to the breast cancer patient population to review the landmark 2008 NEJM article from Sparano et al (https://www.nejm.org/doi/full/10.1056/NEJMoa0707056) investigating the optimal taxane regimen to follow adjuvant AC.
Jul 25, 2019•16 min
Selinexor
A brief discussion on FDA's approval decision on selinexor and its possible role in therapy. Then, a more in-depth details on its MOA, dosing, and toxicity profile.
Jul 18, 2019•15 min
Pain Management In Cancer
An overview of pain management principles in cancer patients. Topics covered include the role of NSAIDs, bisphosphonates, and opioids in treating or preventing pain. Also discussed: bowel regimens & opioid conversions.
Jul 11, 2019•31 min
For the best experience, listen in Metacast app for iOS or Android